Prognostic impact of the multimodal treatment approach in patients with C19MC-altered embryonal tumor with multilayered rosettes

View More View Less
  • 1 Department of Hematology/Oncology and
  • | 2 Department of Radiology, Saitama Children’s Medical Center, Saitama;
  • | 3 Department of Human Pathology, Gunma University Graduate School of Medicine, Maebashi;
  • | 4 Department of Pathology, Public Tomioka General Hospital, Tomioka; and
  • | 5 Department of Clinical Research and
  • | 6 Department of Neurosurgery, Saitama Children’s Medical Center, Saitama, Japan
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
USD  $45.00
USD  $515.00
USD  $612.00
Print or Print + Online Sign in

OBJECTIVE

Embryonal tumor with multilayered rosettes (ETMR) is one of the childhood central nervous system tumors with the poorest prognosis; thus, establishing an optimal treatment strategy is essential, However, because of the low incidence and molecular heterogeneity of the tumor, the optimal treatment has not yet been determined. In this study the authors evaluated the prognostic impact of a multimodal treatment approach in patients with ETMR.

METHODS

The authors evaluated 4 patients with ETMR at their institution who showed varied clinical features and also conducted clinical characterization and prognostic analysis of previously reported cases of the ETMR-presenting locus 19q13.42 with a chromosome 19 microRNA cluster (C19MC) amplification, which is known to be a diagnostic hallmark of the tumor.

RESULTS

Of the 4 patients with ETMR in the authors’ institution, in 1 case the patient’s tumor showed a neuroblastoma-like appearance without multilayered rosettes; however, the diagnosis was confirmed by the presence of amplified C19MC. From a clinical standpoint, 2 patients who underwent gross-total resection (GTR) of the tumor and chemotherapy followed by high-dose chemotherapy (HDC) had long-term complete remission with or without local irradiation. In the multivariate analysis of 43 cases with C19MC-altered ETMR reported in the literature, HDC and local irradiation were significantly correlated with better event-free survival (HR 0.17, p = 0.0087; HR 0.17, p = 0.010) and overall survival (OS) (HR 0.29, p = 0.023; HR 0.28, p = 0.019), respectively. GTR was also correlated with better OS (HR 0.40, p = 0.039).

CONCLUSIONS

This case series demonstrated pathological and clinical heterogeneity among ETMR cases and the diagnostic importance of the molecular genetic approach among embryonal tumors, particularly during infancy. Based on the results of the analysis of molecularly uniformed ETMR cases, multimodal treatment may play a significant role in the prognosis of these tumors.

ABBREVIATIONS

C19MC = chromosome 19 microRNA cluster; CSI = craniospinal irradiation; EFS = event-free survival; ETANTR = embryonal tumor with abundant neuropil and true rosettes; ETMR = embryonal tumor with multilayered rosettes; FISH = fluorescence in situ hybridization; GNB = ganglioneuroblastoma; GTR = gross-total resection; HDC = high-dose chemotherapy; LIN28A = Lin-28 homolog A; OS = overall survival; RT = radiation therapy.

Images from Oushy et al. (pp 195–202).

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
USD  $515.00
USD  $612.00
  • 1

    Paulus W, Kleihues P. Genetic profiling of CNS tumors extends histological classification. Acta Neuropathol. 2010;120(2):269270.

  • 2

    Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803820.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3

    Lambo S, Gröbner SN, Rausch T, et al. The molecular landscape of ETMR at diagnosis and relapse. Nature. 2019;576(7786):274280.

  • 4

    Lambo S, von Hoff K, Korshunov A, Pfister SM, Kool M. ETMR: a tumor entity in its infancy. Acta Neuropathol. 2020;140(3):249266.

  • 5

    Horwitz M, Dufour C, Leblond P, et al. Embryonal tumors with multilayered rosettes in children: the SFCE experience. Childs Nerv Syst. 2016;32(2):299305.

  • 6

    Nobusawa S, Yokoo H, Hirato J, et al. Analysis of chromosome 19q13.42 amplification in embryonal brain tumors with ependymoblastic multilayered rosettes. Brain Pathol. 2012;22(5):689697.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452458.

  • 8

    Pfister S, Remke M, Castoldi M, et al. Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. Acta Neuropathol. 2009;117(4):457464.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9

    Korshunov A, Remke M, Gessi M, et al. Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol. 2010;120(2):253260.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    Wang Y, Chu SG, Xiong J, Cheng HX, Chen H, Yao XH. Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with a focal amplification at chromosome 19q13.42 locus: further evidence of two new instances in China. Neuropathology. 2011;31(6):639647.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11

    Lafay-Cousin L, Hader W, Wei XC, et al. Post-chemotherapy maturation in supratentorial primitive neuroectodermal tumors. Brain Pathol. 2014;24(2):166172.

  • 12

    Nobusawa S, Orimo K, Horiguchi K, et al. Embryonal tumor with abundant neuropil and true rosettes with only one structure suggestive of an ependymoblastic rosette. Pathol Int. 2014;64(9):472477.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Sato H, Terakawa Y, Tsuyuguchi N, Kuwae Y, Ohsawa M, Ohata K. Embryonal tumor with abundant neuropil and true rosettes in the brainstem: case report. J Neurosurg Pediatr. 2015;16(3):291295.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Antonelli M, Korshunov A, Mastronuzzi A, et al. Long-term survival in a case of ETANTR with histological features of neuronal maturation after therapy. Virchows Arch. 2015;466(5):603607.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15

    Tariq MU, Ahmad Z, Minhas MK, Memon A, Mushtaq N, Hawkins C. Embryonal tumor with multilayered rosettes, C19MC-altered: report of an extremely rare malignant pediatric central nervous system neoplasm. SAGE Open Med Case Rep. 2017;5:2050313X17745208.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Pei YC, Huang GH, Yao XH, et al. Embryonal tumor with multilayered rosettes, C19MC-altered (ETMR): a newly defined pediatric brain tumor. Int J Clin Exp Pathol. 2019;12(8):31563163.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17

    Bailey K, Pandit-Taskar N, Humm JL, et al. Targeted radioimmunotherapy for embryonal tumor with multilayered rosettes. J Neurooncol. 2019;143(1):101106.

  • 18

    Hanson D, Hoffman LM, Nagabushan S, et al. A modified IRS-III chemotherapy regimen leads to prolonged survival in children with embryonal tumor with multilayer rosettes. Neurooncol Adv. 2020;2(1):vdaa120.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19

    Mayr L, Gojo J, Peyrl A, et al. Potential importance of early focal radiotherapy following gross total resection for long-term survival in children with embryonal tumors with multilayered rosettes. Front Oncol. 2020;10:584681.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20

    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, eds.WHO Classification of Tumours of the Central Nervous System. Revised 4th ed, vol 1. IARC;2016:408.

    • Search Google Scholar
    • Export Citation
  • 21

    Rao S, Rajeswarie RT, Chickabasaviah Yasha T, Nandeesh BN, Arivazhagan A, Santosh V. LIN28A, a sensitive immunohistochemical marker for embryonal tumor with multilayered rosettes (ETMR), is also positive in a subset of atypical teratoid/rhabdoid tumor (AT/RT). Childs Nerv Syst. 2017;33(11):19531959.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 22

    Li M, Lee KF, Lu Y, et al. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009;16(6):533546.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23

    Korshunov A, Sturm D, Ryzhova M, et al. Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol. 2014;128(2):279289.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24

    Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555(7697):469474.

  • 25

    Manjila S, Ray A, Hu Y, Cai DX, Cohen ML, Cohen AR. Embryonal tumors with abundant neuropil and true rosettes: 2 illustrative cases and a review of the literature. Neurosurg Focus. 2011;30(1):E2.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 26

    Spence T, Sin-Chan P, Picard D, et al. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014;128(2):291303.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27

    Schmidt C, Schubert NA, Brabetz S, et al. Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. Neuro Oncol. 2017;19(12):16071617.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 888 888 240
Full Text Views 47 47 14
PDF Downloads 52 52 22
EPUB Downloads 0 0 0